|
Multicenter Investigation of Limitation of Infarct Size (MILIS) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Multicenter Investigation of Limitation of Infarct Size (MILIS) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Multicenter Investigation of Limitation of Infarct Size (MILIS) Clinical research trials and Multicenter Investigation of Limitation of Infarct Size (MILIS) health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Multicenter Investigation of Limitation of Infarct Size (MILIS). Multicenter Investigation of Limitation of Infarct Size (MILIS) Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Multicenter Investigation of Limitation of Infarct Size (MILIS) clinical trial. Human subjects often get the best healthcare possible for their Multicenter Investigation of Limitation of Infarct Size (MILIS) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Multicenter Investigation of Limitation of Infarct Size (MILIS)  Multicenter Investigation of Limitation of Infarct Size (MILIS)
Multicenter Investigation of Limitation of Infarct Size (MILIS)
For Condition: Cardiovascular Diseases,Coronary Disease,Heart Diseases,Myocardial Infarction,Myocardial Ischemia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.
Details: BACKGROUND: The study of methods for minimizing the mass of ischemic infarcted myocardium associated with a myocardial infarction was identified as a topic of research priority in the 1973 Report of the Panel Chairman for the Preparation of the National Heart, Blood Vessel, Lung, and Blood Program. In September 1976, the Institute convened a workshop involving 32 investigators active in this field, respondents to past solicitations, experts on the topic of collaborative clinical trials, members of previous review committees, and several members of the Cardiology Advisory Committee. The attendees were enthusiastic about the practicality and timeliness of a collaborative clinical trial in this field. The concept of collaborative clinical trials to protect ischemic myocardium was discussed by the Cardiology Advisory Committee in its meeting of September 22, 1976, and was recommended affirmatively and enthusiastically. This trial was part of the Institute's initiatives and was reviewed and favorably recommended by the National Heart, Lung, and Blood Advisory Council at its December 1976 meeting. The trial consisted of five clinical centers, six central laboratories, a clinical coordinating center, and a data coordinating center. DESIGN NARRATIVE: Randomized. Group A patients were randomized to propranolol therapy, hyaluronidase therapy, or control therapy; patients assigned to Group B (propranolol contraindicated) were assigned to hyaluronidase or control therapy. Single-blind for propranolol therapy, double-blind for hyaluronidase or control therapy; fixed sample. Detailed follow-up of clinical status and endpoints for a six-month period; annual health status follow-up thereafter.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/74 Years
Genders: Both
Protocol Entry Criteria: Men and women, under age 75. Documented myocardial infarction which could be treated within 18 hours of onset of ischemic symptoms.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
EugeneBraunwald, , Harvard Medical School, Peter Bent Brigham Hospital
Additional Information:
Study ID Numbers: 12;
Study Start Date: September 1977
Record last reviewed: December 1985
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000493
Other Coronary Disease Studies:
1. Stroke and MI in Users of Estrogen/Progestogen
2. Study of Oral PG-116800 Following a Heart Attack
3. A safety, efficacy trial evaluating the early administration of abciximab and reteplase combination treatment in PCI
4. Program on Surgical Control of Hyperlipidemias (POSCH)
5. Multicenter Investigation of Limitation of Infarct Size (MILIS)
Related Studies:
Other Coronary Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Multicenter Investigation of Limitation of Infarct Size (MILIS)
|
|
|
|
|
|
|
|
